



Biosafety for prevent yourself from New H1N1 Influenzae -about CDC recommendation-

Kazuaki Arai, Infectious Control Microbiologist,
Department of Clinical Microbiology with
Epidemiological Research & Management and
Analysis of Infectious disease, Tohoku University
Graduate school,

Conference of IRTM&Tohoku University at Tacloban, May 20, 2009

Swine Influenza A (H1N1) Virus Biosafety Guidelines for Laboratory Workers

- The Centers for Disease Control and Prevention (CDC) issued this interim laboratory guidance on April 24, 2009
- The text of the document is below and is also available on CDC's website

http://www.cdc.gov/swineflu/guidelines_labworkers.htm.

Outline of CDC Guidline

Note:

- 1.Clinical and hospital labs are strongly encouraged to contact their state <u>public health laboratory</u> for testing recommendations issued by state and local health agencies.
- 2. In most cases, samples from patients highly suspected of having swine influenza A (H1N1) virus, should be mailed as Category B: Infectious substance, but nofatal pathogen, ordinal clinical specimens
- 3. However, members are advised to consult with their state public health agencies for confirmation of this classification and instructions for packing and shipping.

About specimens

- The specimens of choice: Nasopharyngeal swabs, nasal aspirates, nasal swabs, or pharyngeal swabs from patients meeting clinical criteria, risk factors and travel history for possible swine influenza A (H1N1) virus.
- It is strongly recommended that BSL2 with BSL3 protection guidelines be followed when handling specimens.

Rapid Test for distinguishing influenzae A and B

 Individuals performing point-of-care testing may wish to consider performing this testing if they have access to a biological safety cabinet.

What target for ?

- For laboratory workers who may be processing or performing diagnostic testing on clinical specimens from patients with suspected swine influenza A (H1N1) virus infection, or performing viral isolation.
- For equipment that should be conducted in a BSL2 laboratory.(for exsample, a biosafety cabinet (BSC)., mask, goun, goggle,) Especially viral isolation should be performed in a BSL2 laboratory with BSL3 practices (enhanced BSL2 conditions).

Others precaution

- Additional precautions include:
 - Personal Protective Equipment
 (based on site specific risk assessment)
 - N95 respirator or higher level of protection
 - Shoe covers
 Closed-front gown
 - Double gloves
 Goggles or face shields)
- Waste:
 - All waste disposal procedures your facility standard laboratory operating procedures rule
- Appropriate disinfectants:
 - 70% Ethanol 5% Lysol 10% Bleach

After tasting or handling

 Self-monitor (fever, cough, sore throat, vomiting, diarrhea, headache, runny nose, and muscle aches)

(Any illness should be reported to your supervisor immediately.

- If you had unprotected exposure or a known breach in PPE to clinical material or live virus, antiviral chemoprophylaxis with zanamivir or oseltamivir for 7 days after exposure can be considered.
- For more information on the use of antiviral agents for treatment and chemoprophylaxis of swine influenza A (H1N1) virus infection.please see:

http://www.cdc.gov/swineflu/recommendations.htm

For whose this CDC guideline?

- 1st concept is keep safety for laboratory worker
- 2nd concept is keep safety for patients
- 3 rd concept is keep safety for around worker

For Clinic & Hospital function

For Society